Reset filter
Keywords
End of Study ×
Prostatic Neoplasms ×
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

6 Search results.

Relevance Rating New first Old first

Investigator data Log GSK study Prostatic neoplasms NCT00883909

- 11/26/17 - 1 form, 3 itemgroups, 8 items, 1 language
Itemgroups: Administrative data,Investigator Comment,Investigator Statement
Study ID: 103094 Clinical Study ID: ARI103094 Study Title: ARI103094-Follow-Up Study for REDUCE Study Subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00883909 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: dutasteride Trade Name: Zytefor,Zyfetor,Duagen,Avolve,Avodart,Avidart Study Indication: Neoplasms, Prostate CRF Seiten: 934-977

CRFs Cabazitaxel Prostate Cancer DRKS00006520 NCT01308580 End of Treatment - CRFs Cabazitaxel Prostate Cancer NCT01308580 End of Treatment

- 5/25/17 - 1 form, 7 itemgroups, 46 items, 1 language
Itemgroups: End of Treatment,Visit Information,Vital Signs,Laboratory Tests Hematology,Laboratory Tests Biochemistry,Ciruclating free plasma DNA - Blood Sampling,Electrocardiogram
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen Other drug name: Jevtana® Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01308580 Sponsor: Sanofi

Radium-223 Dichloride (Alpharadin) DRKS00006460 NCT01618370 in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases (Survival Follow-up) - Radium 223 Dichloride (Alpharadin) - Survival Follow-up

- 3/30/17 - 1 form, 2 itemgroups, 7 items, 1 language
Itemgroups: Survival Assessment,End of Survival Follow-up
This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC (Hormone refractory prostate cancer / Castrate resistant prostate cancer) patients diagnosed with bone metastasis and to collect additional short and long term safety data on the product. NCT01618370

Radium-223 Dichloride (Alpharadin) DRKS00006460 NCT01618370 in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases (Last Visit) - Radium 223 Dichloride (Alpharadin) - Last Visit

- 3/30/17 - 1 form, 2 itemgroups, 4 items, 1 language
Itemgroups: Last Visit,Death
This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC (Hormone refractory prostate cancer / Castrate resistant prostate cancer) patients diagnosed with bone metastasis and to collect additional short and long term safety data on the product. NCT01618370

Radium-223 Dichloride (Alpharadin) DRKS00006460 NCT01618370 in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases (End of Study Treatment) - Radium 223 Dichloride (Alpharadin) - End of Study Treatment

- 3/20/17 - 1 form, 1 itemgroup, 6 items, 1 language
Itemgroup: End of Study Treatment
This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC (Hormone refractory prostate cancer / Castrate resistant prostate cancer) patients diagnosed with bone metastasis and to collect additional short and long term safety data on the product. NCT01618370

Radium-223 Dichloride (Alpharadin) DRKS00006460 NCT01618370 in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases (End of Treatment Visit) - Radium 223 Dichloride (Alpharadin) - End of Treatment Visit

- 3/20/17 - 1 form, 7 itemgroups, 45 items, 1 language
Itemgroups: Subject Visit,Assessment of Disease Progression,Vital Signs,BPI-SF,ECOG Performance Status,Hematology (with DBC),General Chemistry - Serum
This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC (Hormone refractory prostate cancer / Castrate resistant prostate cancer) patients diagnosed with bone metastasis and to collect additional short and long term safety data on the product. NCT01618370

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial